Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | RORC | P51449 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22953093 | 0.89 | GPR119 (0.57) | USP30GPR119FPR2FPR3ALDH1A1 | |
| SCHEMBL22031700 | 0.89 | NR1H2 (0.50) | USP30GPR119RORCFPR2FPR3 | |
| SCHEMBL3344897 | 0.89 | GPR119 (0.57) | USP30GPR119FPR2FPR3ALDH1A1 | |
| SCHEMBL24467408 | 0.89 | GPR119 (0.57) | USP30GPR119FPR2FPR3ALDH1A1 | |
| SCHEMBL29964707 | 0.87 | CHEK2 (0.55) | USP30GPR119FPR2FPR3ALDH1A1 | |
| SCHEMBL29964863 | 0.87 | CHEK2 (0.55) | USP30GPR119FPR2FPR3ALDH1A1 | |
| SCHEMBL28670992 | 0.87 | USP30 (0.53) | USP30GPR119RORCALDH1A1CHEK2 | |
| SCHEMBL12788093 | 0.87 | USP30 (0.53) | USP30GPR119ALDH1A1CHEK2NR1H2 | |
| SCHEMBL6182215 | 0.87 | USP30 (0.53) | USP30GPR119ALDH1A1CHEK2NR1H2 | |
| SCHEMBL2366151 | 0.86 | GPR119 (0.65) | USP30GPR119FPR2ALDH1A1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4508028-B1 | NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2026-03-11 | — | — | EP | disclosed |
| US-20250368619-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-12-04 | — | — | US | disclosed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-20250250231-A1 | NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2025-08-07 | — | — | US | disclosed |
| EP-4584257-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-16 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119836419-A | Substituted tetrahydrocyclohepta [ E ] indole derivatives, method for the production and therapeutic use thereof | 赛诺菲 | 2025-04-15 | — | — | CN | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4508028-A1 | NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| CN-119451943-A | Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, process for their preparation and their therapeutic use | 赛诺菲 | 2025-02-14 | — | — | CN | disclosed |
| WO-2014140704-A1 | INDOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013153479-A2 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PFIZER INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| EP-2089397-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| WO-2008076562-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | USP30 1928/4885GPR119 223/4885RORC 2991/4885 |
| US-20250250231-A1 | NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR2, ESRRA, CYP19A1 | USP30 3294/4885GPR119 104/4885RORC 487/4885 |
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | USP30 2640/4885GPR119 16/4885RORC 128/4885 |
| US-20130267493-A1 | INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK | PRKAG1, PRKAG3, PRKAG2 | USP30 2802/4885GPR119 52/4885RORC 186/4885 |
| US-20250368619-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, NR5A1, FSHR | USP30 2216/4885GPR119 33/4885RORC 235/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | USP30 2406/4885GPR119 16/4885RORC 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.